{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327600/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327600"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of clofazimine treatment on functional gene transcription in hepatocellular carcinoma cells","description":"Clofazimine (CFZ) is an orally administered anti-mycobacterial drug that demonstrates a broad spectrum of activity against mycobacterial infections, including leprosy and tuberculosis. CFZ also possesses anti-inflammatory and anti-tumor properties by disrupting DNA replication and inhibiting the production of IL2. Currently, this compound has been utilized in research related to drug-resistant cancer treatment, and has gained increasing recognition for its potential to enhance cancer treatment in recent years. Considering the benefits of CFZ in clinical settings, it presents itself as a promising candidate for combination drug therapy aimed at hepatocellular carcinoma through the regulation of functional gene transcription. Herein, we primarily examine the role of CFZ treatment throughout the functional gene transcription process in hepatocellular carcinoma cells.","dates":{"publication":"2026/04/15"},"accession":"GSE327600","cross_references":{"GSM":["GSM9662082","GSM9662083","GSM9662080","GSM9662081"],"GPL":["34284"],"GSE":["327600"],"taxon":["Homo sapiens"]}}